People who know me know I am not a conspiracy nut. I’m a journalist and I deal in facts. Facts have contexts and once the facts are dug up, they must be put into context.
What is amazing about journalism today is that bullshit is published everywhere and readers are bombarded with it daily through gaslighting, and since critical thinking is eschewed, most people simply suck it all in unquestioningly.
Modern medicine has very little basis in science, which we have documented. Modern medicine is a business with the bottom line being the almighty dollar and lots of them. Profit is the bottom line. We like to call it Profit-Based Medicine.
Modern medicine is a monopoly and like any monopoly it is solely aimed at destroying competition to gain complete market share.
Anything that stands in the way of profiting is attacked, buried, burned, and ultimately destroyed.
This is what has happened to a 1997 vaccine against HIV/AIDS. It would have killed profits from drug companies selling viciously expensive drugs needed to keep HIV positive patients alive. We’ve all heard of that so-called cocktail, and the more people who get infected, the more that cocktail is sold.
Additionally, this vaccine, when taken by a person with HIV infection, protects all the body’s cells that have not been infected with the virus.
When Dr Sam Chachoua went on television, the skeptic community reeled in laughter, roaring over the quack idea that milk from goats with arthritis could fight HIV. It was just lots of fun and games pointing fingers at the quack doctor.
I’m have two images (posted below) but first I have written out the actual text for all to read from a study showing proof the use of this goat virus in preventing HIV. If you want to laugh, go ahead, but keep in mind always that no amount of proof can convince a skeptic of anything that goes against his/her belief system. And that belief system has nothing to do with science.
(AW) Conference Coverage (NCVDG): Goat Virus May Protect Against HIV
AIDSWEEKLY Plus, Monday, 2 June 1997
Daniel J. DeNoon, Senior Editor
Humans infected with a harmless goat virus develop antibodies that neutralize HIV.
The remarkable finding offers hope for a safe, attenuated AIDS vaccine using the goat virus or a genetically engineered variant carrying HIV genes. It is strikingly reminiscent of the. Earliest vaccine: Edward Jenner’s discovery that a relatively harmless cow virus (cowpox or vaccinia) could protect humans against smallpox.
The goat virus is caprine arthritis-encephalitis virus (CAEV).
“A major obstacle to designing live attenuated vaccines using primate lentiviruses is the substantial health threat to humans,” noted Angeline Douvas of the University of Southern California, Los Angeles.
“Human-infecting CAEV-like lentiviruses with low pathogenicity may have prophylactic applications against HIV-1 as vaccines, as chimeras with HIV-1 (CHIVs), or as competitors for binding to target-cell receptors.”
Douvas reported the findings in a report to the 9th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS (NCVDG), held May 4-7, 1997, in Bethesda, Maryland.
CAEV is a monocyte macrophage-tropic virus with worldwide distribution. At least 65 percent of goats carry the. virus; some 85 percent of goat herds are infected. About 40 percent of infected animals develop symptoms of arthritis, mastitis (breast inflammation), and/or encephalitis.
Human infection, which is non-pathogenic, occurs mainly through ingestion of raw goat milk.
CAEV variants capable of infecting humans were first detected in people with mixed connective tissue disease (MCTD), an immune deficiency with clinical features similar to those of systemic lupus erythematosus (SLE). But CAEV is not etiologically linked to MCTD, and human-infecting variants (h- CAEV) have been isolated from healthy people, predominantly of Mexican descent.
h-CAEV is endemic in Mexico; 24 to 39 percent of children with Mexican parents are seropositive for CAEV.
DNA analysis shows that h-CAEV is similar to goat CAEV and is not a distinct lentivirus. hCAEV can be passed in culture to human peripheral blood mononuclear cells (PBMC) via plasma from infected individuals.
Douvas and colleagues became interested in the potential of CAEV as an AIDS vaccine when they learned that some Hispanic MCTD patients tested positive for anti-HIV antibodies even though they were not infected with the AIDS virus.
They found that h-CAEV antibodies from some subjects reacted to both the CAEV gp135 surface glycoprotein and the HIV-1 gp120 envelope glycoprotein. Moreover, these anti-CAEV antibodies were capable of “substantially neutralizing HIV-1.”
Douvas’s group analyzed antibody reactivity from four groups of human subjects:
- Hispanic MCTD patients (n=33). Antibodies from 91 percent recognized CAEV gp135, 61 percent recognized HIV gp120, and 65 percent had dual reactivity.
- Normal Hispanic volunteers (n=l6). Antibodies from 63 percent recognized CAEV gp135, 25 percent recognized HIV gp120, and 40 percent had dual reactivity.
- People with occupational exposure to CAEV (n=2). Antibodies from both subjects recognized CAEV gp135; one had antibodies that recognized HIV gp120 and one had antibodies with dual reactivity.
- HIV-1 positive individuals (n=10). Antibodies from 10 percent recognized CAEV gp135, 100 percent recognized HIV gp120, and 10 percent had dual reactivity.
Dovas and colleagues hypothesized that h-CAEV variants that elicit both gp135 and gp120 antibodies (++ variants) arose from a combination of variants that recognized only CAEV gp135 (+-variants) or only HIV gp120 (-+variants). They further suggested that the ++ variants have structures resembling gp120.
Analysis of CAEV strains from goats and sheep shows that they carry motifs that have been associated with macrophage-tropic strains of HlV-1. These strains current!): ace thought to be responsible for the vast majority of HIV infections.
Douvas suggested that CAEV variants potentially could be used as a live attenuated vaccine for AIDS. The immunity elicited by such vaccines could be increased by creating chimeric CAEV/HIV variants (CHI\/). In addition to eliciting antibody responses that could protect against HIV, CAEV might block the cellular receptors HIV needs to establish infection
Of great interest to vaccine studies is the finding that macaque monkeys can be- infected with h-CAEV, paving the way for studies in a relevant animal model.
970602
AW970601
http://www.aegjs.com/default.asp…
[That link no longer works, however it was where this piece had been first posted.]The actual study is below in an image file.
